Is KNSA or NBIX more undervalued in 2026?

CirclFi compares Kiniksa Pharmaceuticals Interna (KNSA) and Neurocrine Biosciences, Inc. (NBIX) using 13 institutional-grade valuation models. KNSA has a Quality of Company score of 5.5/10 while NBIX scores 10.0/10.

Which is a better buy — KNSA or NBIX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KNSA and NBIX valuations compare?

KNSA at $50.84 and NBIX at $156.39 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KNSA vs NBIX Valuation Comparison 2026 — Intrinsic Value Analysis

KNSA

Drug Manufacturers - Specialty & Generic

Kiniksa Pharmaceuticals Interna

Quality

5.5

out of 10

Value Trap

SAFE

Price

$50.84

Last close

Models

13/13

Active

NBIX

Drug Manufacturers - Specialty & Generic

Neurocrine Biosciences, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$156.39

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KNSA Fair Value	KNSA Upside	NBIX Fair Value	NBIX Upside
Bayesian DCF	Intrinsic	$6.16	-87.9%	$121.05	-22.6%
Earnings Power Value	Intrinsic	$9.70	-80.9%	$34.99	-77.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KNSA vs NBIX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KNSA vs NBIX — Which Stock Is More Undervalued?

NBIX scores higher with a 10.0/10 quality rating vs KNSA's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kiniksa Pharmaceuticals Interna (KNSA) and Neurocrine Biosciences, Inc. (NBIX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KNSA currently trades at $50.84 with a QOC of 5.5/10, while NBIX trades at $156.39 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).